J. Vaccine therapy for cancer. Ann. Surg. Oncol., 3: 219 -228, 1996.Linehan, D. , Goedegebuure, P. , and Eberlein, T. , Vaccine therapy for cancer: A review . Ann. surg. Oncol. , 3 , 219 – 228 ( 1996 ). TODO: clickthrough URL Medline...
Promising results were obtained in clinical trials, but issues of tumor immunosuppression and lack of identified tumor-associated antigens must be addressed before vaccine therapy can be applied successfully in advanced renal cell cancer.doi:10.1586/14760584.7.7.925Amato...
Clinical results of vaccine therapy for cancer: learning from history for improving the future. Adv Cancer Res 2006; 95: 147-202.Choudhury A, Mosolits S, Kokhaei P et al. Clinical results of vaccine therapy for cancer: learning from history for improving the future. Adv Cancer Res 2006; ...
Vaccination therapy for pancreatic cancer is moving into an exiting area with opportunities to attack not only the tumour as such, but also to deal with important regulatory mechanisms that have negatively influenced clinical efficacy so far.
P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma Cancer vaccine therapy is one of the most attractive therapies as a new treatment procedure for pancreatic adenocarcinoma. Recent technical advances have e... T ...
Therapeutic failures may thus be avoided.doi:10.1007/0-387-21600-6_33Eileen M. O'ReillySpringer New YorkO'Reilly EM: Vaccine therapy for pancreatic cancer. In: Pancreatic Cancer, Evans DB, Pisters PWT, Abbruzzese JL (Ed), pp 347-356, Springer-Verlag, New York, 2002....
Iconography : VACCINE THERAPY FOR PROSTATE CANCERBenjamin A TjoaAbdelAziz A ElgamalGerald P Murphy
In: Bot A, Obrocea M, Marincola FM (eds) Cancer vaccines: from research to clinical practice editors, 1st edn. Informa Healthcare, Geneva, pp 217–231S. Nair, D. Boczkowski, S. Pruitt, J. Urban, "RNA in cancer vaccine therapy," in Cancer Vaccines: From Research to Clinical Practice...
Therefore, further improvement of this promising cancer therapy is urgently required in order to optimize its clinical efficacy. In this review, we briefly summarize the history and current status of DC-tumor fusion vaccines. Then, we focus on discussions of the technology and the clinical ...
cancerImmunotherapy with vaccines represents a novel, targeted nontoxic modality for the therapy of prostate cancer. Systemic immune responses to candidate prostate cancer antigens have been induced in a tumor that has been conventionally viewed as refractory to immunotherapy. Autologous dendritic cell ...